arrow
T

Teresa Beninato

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:11
被引数:380

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Chronobiological Prognostic Model for Resected Stage I Non-Small-Cell Lung Cancer

基于昼夜节律的预后模型用于切除的I期非小细胞肺癌

Cancers
IF4.4
2026-10-050
OA
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

可解释AI决策支持工具的临床可用性及非小细胞肺癌中多模态模型的评估

2026-09-130
OAAI
Leave No Data Behind: Exploring a new paradigm in oncology with foundation models and large language models

不留数据:探索基于基础模型和大型语言模型的肿瘤学新范式

2026-08-040
OAAI
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

网络分析预测PD-L1<50%的晚期NSCLC对pembrolizumab的应答

2026-03-260
OA
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
CXCR4 Expression Increases in Platinum-Based Treated Non-Small Cell Lung Cancer and is Associated with a Worsening Trend in Progression Free Survival e A Clinical-Based Population Study Confirms Preclinical Models
2025-03-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma (vol 203C, 104481, 2024)
2024-12-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma
2024-11-012
OAAI
Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy
2024-03-220
PRE
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
2023-11-011
OAAI
Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations
2023-04-040
PRE
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
2023-01-2311
OAAI
Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
2022-09-011
OA
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy

中性粒细胞与淋巴细胞比值和EPSILoN评分在接受一线化疗免疫治疗的晚期非小细胞肺癌患者中的预后作用

2022-06-204
PRE
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
2022-01-0113
PRE